Boehringer Ingelheim and Lilly announce Trajenta’s CARMELINA cardiovas
Trajenta demonstrates long-term cardiovascular safety in adults with type 2 ...
2018-07-24
文传商讯
Boehringer Ingelheim and Lilly announce positive top-line Phase III dat
INGELHEIM, Germany and INDIANAPOLIS--(BUSINESS WIRE)--Boehringer Ingelheim a...
2018-06-26
文传商讯
Jardiance® reduced risk of cardiovascular death in adults with type
Empagliflozin (marketed as Jardiance) reduced the risk of cardiovascular dea...
2017-11-15
文传商讯
Jardiance® (empagliflozin) becomes first type 2 diabetes medicine i
This is the first time the European Commission approved the use of a diabete...
2017-02-06
文传商讯
CHMP adopts a positive opinion acknowledging that Jardiance reduces the
In the EMPA-REG OUTCOME® trial Jardiance® reduced the risk of cardio...
2016-12-20
文传商讯
U.S. FDA approves Jardiance (empagliflozin) tablets to reduce the risk
First and only type 2 diabetes treatment approved to reduce cardiovascular d...
2016-12-07
文传商讯
Jardiance (empagliflozin) consistently reduced the risk of cardiovascul
Results from an analysis of the landmark EMPA-REG OUTCOME trial were present...
2016-11-15
文传商讯
Glyxambi (empagliflozin/linagliptin) approval recommended by CHMP for a
Glyxambi is a single tablet that combines Jardiance and Trajenta and has bee...
2016-09-20
文传商讯
Jardiance (empagliflozin) significantly reduced the risk of progressive
Jardiance® (empagliflozin) is the only SGLT2 inhibitor to demonstrate th...
2016-06-17
文传商讯
New Jardiance® (empagliflozin) data show that reduced risk for card
In a separate analysis, Jardiance® also reduced risk for CV events consi...
2016-06-15
文传商讯
